International Journal of Cardiology
Volume 139, Issue 2 , Pages 187-192 , 4 March 2010

Myeloperoxidase may contribute to the no-reflow phenomenon in patients with acute myocardial infarction

Received 18 March 2008 ,Revised 29 July 2008 ,Accepted 12 October 2008.

References 

  1. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615–1622
  2. Simes RJ, Topol EJ, Holmes DR, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. GUST-1 Investigators. Circulation. 1995;91:1923–1928
  3. Stone GW, Brodie BR, Griffin JJ, et al. Prospective, multicenter study of safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators. J Am Coll Cardiol. 1998;31:23–30
  4. Stone GW, Grins CL, Browne KF, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am Coll Cardiol. 1995;25:370–377
  5. Stone GW, Broody BR, Griffin JJ, et al. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation. 1999;99:1548–1554
  6. The GUSTO IIb Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621–1628
  7. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999;341:1949–1956
  8. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of ‘no reflow’ after percutaneous coronary intervention. Circulation. 1994;89:2514–2518
  9. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-control trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998;98:734–741
  10. Kaul U, Singh B, Sudan D, et al. Primary stenting in acute myocardial infarction: a 30-day follow up study. Cathet Cardiovasc Interv. 1999;46:734–741
  11. Yip HK, chen MC, Chang HW, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest. 2002;122:1322–1332
  12. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105:656–662
  13. Kotani J, Nanto S, Mintz GS, et al. Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation. 2002;24:1672–1677
  14. Katayama T, Kubo N, Takagi Y, et al. Relation of atherothrombosis burden and volume detected by intravascular ultrasound to angiographic no-reflow phenomenon during stent implantation in patients with acute myocardial infarction. Am J Cardiol. 2006;97:301–304
  15. Aiello EA, Jabr RI, Cole WC. Arrhythmia and delayed recovery of cardiac action potential during reperfusion after ischemia: role of oxygen radical-induced no-reflow phenomenon. Circ Res. 1995;77:153–162
  16. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the “no reflow” phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93:223–228
  17. Gerber BL, Rochitte CE, Melin JA, et al. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation. 2000;101:2734–2741
  18. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000;36:1202–1209
  19. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;106:2894–2900
  20. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440–1445
  21. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–1604
  22. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106:2894–2900
  23. Kojima S, Sakamoto T, Ishibara M, et al. The white blood cell count is an independent predictor of no-reflow and mortality following acute myocardial infarction in the coronary intervention era. Ann Med. 2004;36:153–160
  24. Funayama H, Ishikawa S, Kubo N, Yasu T, Saito M, Kawakami M. Increases in interleukin-6 and matrix metalloproteinase-9 in the infarct-related coronary artery of acute myocardial infarction. Circ J. 2004;68:451–454
  25. Kaltoft A, Bøttcher M, Nielsen SS, et al. Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction: a randomized, controlled trial. Circulation. 2006;114:40–47
  26. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. N Eng J Med. 1985;31:932–936
  27. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative methods assessing coronary artery flow. Circulation. 1996;93:879–888
  28. Gibson CM, Murphy SA, Rizzo MJ, et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation. 1999;99:1945–1950
  29. Sato H, Iida H, Tanaka A, et al. The decrease of plaque volume during percutaneous coronary intervention has a negative impact on coronary flow in acute myocardial infarction: a major role of percutaneous coronary intervention-induced embolization. J Am Coll Cardiol. 2004;44:300–304
  30. Van't Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction. Zwolle Myocardial Infarction Study Group. Circulation. 1998;97:2302–2306
  31. Henriques JP, Zijlstra F, van't Hof AW, et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation. 2003;107:2115–2119
  32. Haager PK, Christott P, Heussen N, Lepper W, Hanrath P, Hoffmann R. Prediction of clinical outcome after mechanical revascularization in acute myocardial infarction by marker of myocardial reperfusion. J Am Coll cardiol. 2003;41:532–538
  33. Buffon A, Biasucci LM, Liuzzo G, D'onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5–12
  34. Dinerman JL, Mehta JL, Saldeen TP, et al. Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol. 1990;15:1559–1563
  35. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokine-CXC and CC chemokines. Adv Immunol. 1994;55:97–179
  36. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J. 1992;6:2591–2599
  37. Karakurum M, Shreeniwas R, Chen J, et al. Hypoxic induction of interleukin-8 gene expression in human endothelial cells. J Clin Invest. 1994;93:1564–1570
  38. Schroder JM, Mrowietz U, Christophers E. Purification and partial biologic characterization of a human lymphocyte-derived peptide with potent neurtrophil-stimulating activity. J Immunol. 1998;140:3534–3540
  39. Coats AJ. Ethical authorship and publishing. Int J Cardiol. 2009;131:149–150

PII: S0167-5273(08)01093-0

doi: 10.1016/j.ijcard.2008.10.018

International Journal of Cardiology
Volume 139, Issue 2 , Pages 187-192 , 4 March 2010

Article Tools

* Image Usage & Resolution